ciprofloxacin has been researched along with Obesity in 7 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first study to show a positive association of enrofloxacin internal exposure with overweight or obesity risk in children, demonstrating that more attention should be given to the usage and disposal of fluoroquinolones to safeguard children's health." | 4.12 | Association between fluoroquinolone exposure and children's growth and development: A multisite biomonitoring-based study in northern China. ( Gao, M; Li, H; Li, W; Pan, X; Shan, L; Tian, H; Wang, J, 2022) |
| "To describe the pharmacokinetic profile and clinical outcome associated with high-dose ciprofloxacin therapy in a patient with the triad of extreme obesity, multiple organ failure, and deep-seated infection." | 3.76 | High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ( Callcut, RA; Healy, DP; Hurford, WE; Mueller, EW; Peterson, JD; Utrup, TR, 2010) |
| "Obesity is a growing problem in the United States." | 1.38 | Underdosing of common antibiotics for obese patients in the ED. ( Fuentes, JM; Mullins, ME; Roe, JL, 2012) |
| "To investigate whether weight adjusted ciprofloxacin dosing results in comparable target site concentrations in obese and lean subjects." | 1.31 | Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. ( Brunner, M; Hollenstein, UM; Müller, M; Schmid, R, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Shan, L | 1 |
| Gao, M | 1 |
| Pan, X | 1 |
| Li, W | 1 |
| Wang, J | 1 |
| Li, H | 1 |
| Tian, H | 1 |
| Chen, AF | 1 |
| Riedel, S | 1 |
| García Callejo, J | 1 |
| Utrup, TR | 1 |
| Mueller, EW | 1 |
| Healy, DP | 1 |
| Callcut, RA | 1 |
| Peterson, JD | 1 |
| Hurford, WE | 1 |
| Roe, JL | 1 |
| Fuentes, JM | 1 |
| Mullins, ME | 1 |
| Allard, S | 1 |
| Kinzig, M | 1 |
| Boivin, G | 1 |
| Sörgel, F | 1 |
| LeBel, M | 1 |
| Hollenstein, UM | 1 |
| Brunner, M | 1 |
| Schmid, R | 1 |
| Müller, M | 1 |
7 other studies available for ciprofloxacin and Obesity
| Article | Year |
|---|---|
Association between fluoroquinolone exposure and children's growth and development: A multisite biomonitoring-based study in northern China.
Topics: Animals; Anti-Bacterial Agents; Biological Monitoring; Child; China; Ciprofloxacin; Enrofloxacin; Fl | 2022 |
A Case Illustrating the Practical Application of the AAOS Clinical Practice Guideline: Diagnosis and Prevention of Periprosthetic Joint Infection.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Biomarkers; Ceftazidime; Ciprofloxacin | 2020 |
Psoas and neck abscess by Nocardia farcinica.
Topics: Aged; Aminoglycosides; Ciprofloxacin; Coinfection; Drainage; Humans; Linezolid; Male; Neck; Nocardia | 2019 |
High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration.
Topics: Anti-Infective Agents; Ciprofloxacin; Critical Illness; Enterobacter aerogenes; Enterobacteriaceae I | 2010 |
Underdosing of common antibiotics for obese patients in the ED.
Topics: Anti-Bacterial Agents; Bacterial Infections; Body Weight; Cefazolin; Cefepime; Cephalosporins; Cipro | 2012 |
Intravenous ciprofloxacin disposition in obesity.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Infusions, Intravenous; Male; | 1993 |
Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; Ciprofloxacin; | 2001 |